Hologic, Inc. (HOLX) Given Consensus Recommendation of “Buy” by Brokerages

Shares of Hologic, Inc. (NASDAQ:HOLX) have been given a consensus rating of “Buy” by the sixteen analysts that are presently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, three have given a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company. The average 1-year price target among analysts that have covered the stock in the last year is $48.79.

A number of research firms recently weighed in on HOLX. Needham & Company LLC reissued a “buy” rating and set a $50.00 target price (up from $48.00) on shares of Hologic in a research report on Tuesday, January 9th. BidaskClub downgraded Hologic from a “hold” rating to a “sell” rating in a research report on Saturday. Cowen raised Hologic to a “buy” rating and set a $52.00 target price on the stock in a research report on Wednesday, December 20th. Bank of America raised Hologic from a “neutral” rating to a “buy” rating and set a $50.00 target price on the stock in a research report on Thursday, January 4th. Finally, Evercore ISI began coverage on Hologic in a research report on Wednesday, January 3rd. They set an “outperform” rating and a $50.00 target price on the stock.

In other Hologic news, VP Karleen Marie Oberton sold 1,256 shares of the firm’s stock in a transaction dated Wednesday, November 8th. The shares were sold at an average price of $39.29, for a total transaction of $49,348.24. Following the completion of the transaction, the vice president now owns 9,406 shares in the company, valued at $369,561.74. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Elaine Ullian sold 9,282 shares of the firm’s stock in a transaction dated Monday, November 13th. The stock was sold at an average price of $40.50, for a total transaction of $375,921.00. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 12,099 shares of company stock valued at $487,223. Corporate insiders own 0.79% of the company’s stock.

Institutional investors and hedge funds have recently made changes to their positions in the business. Grove Bank & Trust raised its stake in shares of Hologic by 115.8% in the third quarter. Grove Bank & Trust now owns 2,860 shares of the medical equipment provider’s stock valued at $105,000 after acquiring an additional 1,535 shares during the last quarter. Hall Laurie J Trustee raised its stake in shares of Hologic by 10.2% in the second quarter. Hall Laurie J Trustee now owns 2,425 shares of the medical equipment provider’s stock valued at $110,000 after acquiring an additional 225 shares during the last quarter. Commonwealth Bank of Australia raised its stake in shares of Hologic by 31.0% in the second quarter. Commonwealth Bank of Australia now owns 2,533 shares of the medical equipment provider’s stock valued at $114,000 after acquiring an additional 600 shares during the last quarter. MPS Loria Financial Planners LLC bought a new position in shares of Hologic in the second quarter valued at approximately $191,000. Finally, National Asset Management Inc. bought a new position in shares of Hologic in the second quarter valued at approximately $203,000. Hedge funds and other institutional investors own 97.58% of the company’s stock.

Shares of Hologic (NASDAQ HOLX) opened at $43.71 on Tuesday. The stock has a market capitalization of $12,050.13, a PE ratio of 16.56, a PEG ratio of 2.09 and a beta of 0.95. Hologic has a 1 year low of $35.76 and a 1 year high of $46.80. The company has a debt-to-equity ratio of 0.79, a current ratio of 0.79 and a quick ratio of 0.61.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings results on Wednesday, November 8th. The medical equipment provider reported $0.50 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.49 by $0.01. Hologic had a return on equity of 21.69% and a net margin of 24.70%. The company had revenue of $802.90 million for the quarter, compared to the consensus estimate of $792.54 million. During the same period last year, the business posted $0.52 earnings per share. The firm’s revenue was up 10.5% compared to the same quarter last year. sell-side analysts predict that Hologic will post 2.15 EPS for the current year.

WARNING: “Hologic, Inc. (HOLX) Given Consensus Recommendation of “Buy” by Brokerages” was first published by American Banking News and is the property of of American Banking News. If you are reading this article on another domain, it was illegally stolen and reposted in violation of US and international trademark & copyright legislation. The legal version of this article can be read at https://www.americanbankingnews.com/2018/01/16/hologic-inc-holx-given-consensus-recommendation-of-buy-by-brokerages-2.html.

About Hologic

Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.

Analyst Recommendations for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply